Journal
CELL
Volume 177, Issue 4, Pages 1035-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2019.03.030
Keywords
-
Categories
Funding
- National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) [U24CA159988, U24CA210954, U24CA160019, U24CA210955]
- Cancer Prevention & Research Institutes of Texas [CPRIT RR160027]
- McNair Medical Institute at The Robert and Janice McNair Foundation
- DOE [DE-AC05-76RL01830]
Ask authors/readers for more resources
We performed the first proteogenomic study on a prospectively collected colon cancer cohort. Comparative proteomic and phosphoproteomic analysis of paired tumor and normal adjacent tissues produced a catalog of colon cancer-associated proteins and phosphosites, including known and putative new biomarkers, drug targets, and cancer/testis antigens. Proteogenomic integration not only prioritized genomically inferred targets, such as copy-number drivers and mutation-derived neoantigens, but also yielded novel findings. Phosphoproteomics data associated Rb phosphorylation with increased proliferation and decreased apoptosis in colon cancer, which explains why this classical tumor suppressor is amplified in colon tumors and suggests a rationale for targeting Rb phosphorylation in colon cancer. Proteomics identified an association between decreased CD8 T cell infiltration and increased glycolysis in microsatellite instability-high (MSI-H) tumors, suggesting glycolysis as a potential target to overcome the resistance of MSI-H tumors to immune checkpoint blockade. Proteogenomics presents new avenues for biological discoveries and therapeutic development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available